Indirect treatment comparison of asthma biologics fraught with methodology issues

We read with interest the article by Busse et  al1 that evaluated the relative efficacies of benralizumab 30 mg, mepolizumab 100 mg, and reslizumab 3 mg/kg through an indirect treatment comparison (ITC). After careful consideration, we have concluded the methodology was lacking, and, therefore, the results and conclusions may not be robust or replicable. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://bit.ly/2VMqiHY